Navigation Links
Patient Advocates File FOIA Request to FDA on Avastin
Date:4/27/2011

WASHINGTON, April 27, 2011 /PRNewswire/ -- Leaders in the battle with the U.S. Food and Drug Administration to retain metastatic breast cancer (mbc) as an indication for the drug Avastin today filed a Freedom of Information Act ("FOIA") request with the FDA.

The filers include noted attorney David Rivkin, partner at the law firm Baker Hostetler (www.bakerlaw.com/davidbrivkinjr/), Frank Burroughs and Steven Walker on behalf of the Abigail Alliance for Better Access to Developmental Drugs (www.abigail-alliance.org) campaigners for increased access to experimental drugs and Terrence Kalley on behalf of Freedom of Access to Medicines (www.fameds.org), an organization dedicated to the right of women to retain Avastin as a medical option for mbc.

The filers are troubled by many actions of the FDA in its review of the drug Avastin, a drug relied upon by an estimated 17,500 women with incurable mbc.  Forty thousand American women die each year from metastatic breast cancer.  Many woman and their oncologists report great success with the drug, yet the FDA will remove the indication for mbc, subject to a final appeal by the drug's manufacturer on June 28th & 29th at the FDA's headquarters in Silver Spring, Maryland.

The FOIA request includes documents regarding the nominations, appointment, actions and communications of the Oncologic Drugs Advisory Committee (ODAC) that will hear the appeal. Even though this panel will render a life and death decision at the June hearings, no patients or their advocates are allowed to speak and many may not be able to attend as the FDA claims space limitations.

The FOIA request also seeks documents regarding the processes by which the FDA reached its conclusions regarding Avastin, the communications between the FDA and various outside parties, any discussions related to the costs of Avastin in the FDA review process, conflicts of interest by those party to the Avastin decision, and other relevant issues.

The filers also seek the scientific basis for the FDA's decision with document requests related to risk and benefit evaluation of Avastin, comparison of the risk / benefit of Avastin versus current approved drugs, the use of progression free survival as a primary end point in cancer drug evaluation and the FDA's criteria for evaluation of toxicity under its Accelerated Approval Process.

The European Medicines Agency's advisory board recommended on April 15th, 2011 expanded use for Avastin for mbc. This follows the National Comprehensive Cancer Network's (an organization of leading U.S. cancer centers treating 160,000 patients per year) second vote to confirm retaining Avastin for use with mbc. The FOIA request includes documents related to how the FDA's decision-making process reached the opposite conclusion on Avastin from these bodies.    

CONTACT:  Rachel Partain, +1-248-404-0722, socialmedia@aqabatech.com


'/>"/>
SOURCE Freedom of Access to Medicines
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Less than One-Third of Patients Taking Montelukast (Singulair®) Therapy for Asthma or Allergies without Trying First-Line Medications End Up Staying on the Medication
2. For Patients on Statins, Study Finds Filling 90 Day Supply Prescriptions through Mail Service Compared to Retail Pharmacy is Associated with Less Waste
3. LATEST Medical Introduces New Kind of Patient Information Web Site - LATESTBreastCancer.com
4. TeleTrackings Patient Flow Dashboard XT™ Stops Operational Problems Before They Start
5. FDA Approves Lamictal®XR™ (Lamotrigine) for Conversion to Monotherapy for Treatment of Partial Seizures in Appropriate Patients
6. HemaQuest Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study of HQK-1001 in Patients With Sickle Cell Disease
7. Robotic Couch Provides Extra Degree of Precision for Patients Undergoing Radiation Therapy for Cancer
8. Digital Assent Signs 100th PatientPad® Customer
9. Banner Health and Poudre Valley Health System Collaborate to Improve Patient Care in Northern Colorado
10. New Published Study Finds Masimo Noninvasive SpCO Effective for Screening Emergency Department Patients for Carbon Monoxide Poisoning
11. Amgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851 in Patients With Postmenopausal Osteoporosis (PMO)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 ... Tomorrow,s Leaders Scholarship is any indication, the future is ... online at www.diabetesscholars.org by the Diabetes Scholars ... in the way of academic and community service excellence. ... program since 2012, and continues to advocate for people ...
(Date:6/23/2016)... 23, 2016  Guerbet announced today that it has ... Horizon Award . One of 12 suppliers ... for its support of Premier members through exceptional local ... and commitment to lower costs. ... of our outstanding customer service from Premier," says ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their ... Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... Pro X users can now reveal the media of their split screens with ...
(Date:6/27/2016)... Lafayette, California (PRWEB) , ... ... ... a pioneer in the patient payment industry today announced its strategic partnership ... and health system workflows. , The two companies’ proven, proprietary technology combine ...
(Date:6/27/2016)... ... , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy Eyeglasses, ... the United States and Canada wear eyeglasses. Once considered to be a purely functional ... a fashion statement. Even celebrities use glasses as a way of creating an iconic ...
(Date:6/26/2016)... ... ... On June 10-11, 2016, A Forever Recovery, a holistic treatment center for ... Table in Battle Creek, MI, where the rehabilitation facility is located. This annual celebration ... world’s leading providers of cereal and other breakfast foods. Its residents often refer to ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
Breaking Medicine News(10 mins):